Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
Many recent advances in basic cell biology and immunology are a harbinger of progress in adoptive cell therapy (ACT) including (1) the finding that host lymphodepletion enhances engraftment and efficacy, (2) the recognition that in vitro T cell functions may not correlate with in vivo efficacy, and (3) the development of advanced ex vivo culture methods to expand lymphocytes to therapeutically effective numbers. In this article, we focus on the development of artificial antigen presenting cells (aAPCs) in our laboratory and their applicability to augment ACT protocols. We also describe how aAPCs can be used to broaden ACT to treat patients with a wide variety of cancers, chronic infectious diseases, and autoimmune manifestations.
Paulos
Chrystal M
CM
Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 554, 421 Curie Boulevard, Philadelphia, PA, 19104-6160, USA.
Suhoski
Megan M
MM
Plesa
Gabriela
G
Jiang
Tianying
T
Basu
Samik
S
Golovina
Tatiana N
TN
Jiang
Shuguang
S
Aqui
Nicole A
NA
Powell
Daniel J
DJ
Levine
Bruce L
BL
Carroll
Richard G
RG
Riley
James L
JL
June
Carl H
CH
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D020014:K562 Cells; D008213:Lymphocyte Activation / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000637:transplantation*